Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Name: Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Published: 2012
License: Public Domain

Gilead Sciences · 2012

ClinicalTrials.gov · Datasets · License: Public Domain · 2012

Open Source ↗

monoclonal-antibody

liver fibrosis due to nash, nash, noncirrhotic, monoclonal antibody, loxl2, simtuzumab, nonalcoholic steatohepatitis, nafld, liver biopsy, mre, liver fibrosis, ishak

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 979600
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.